Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:05:11.075Z.
Calculation as of: 2026-10-06T20:05:11.075Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48a9c173a70739b1093346a936f860d9c8f80d7eeb2565194c7199b3c596865c
PE RATIO
N/A
Market Cap
$376.01M
PE Ratio
N/A
TTM Avg
4952.81
3Y Avg
4952.81
5Y Avg
4952.81
Market Cap
$369.50M
PE Ratio
N/A
TTM Avg
20.42
3Y Avg
20.42
5Y Avg
20.42
Market Cap
$359.53M
PE Ratio
N/A
TTM Avg
170.63
3Y Avg
170.63
5Y Avg
170.63
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zura Bio Limited (ZURA) | $376.19M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | N/A | 4952.81 | 4952.81 | 4952.81 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | N/A | N/A | N/A | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | N/A | 157.27 | 122.07 | 183.95 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | N/A | 20.42 | 20.42 | 20.42 |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | N/A | 13.34 | 13.34 | 21.63 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 170.63 | 170.63 | 170.63 |
| Shoulder Innovations, Inc. (SI)vs › | $396.31M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.96
Forward EPS (Est.)
$-0.82
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
